Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review examines the use of tadalafil and finasteride as a combined therapy for BPH, suggesting it may effectively reduce treatment-related sexual adverse events and improve symptom relief.

This study validated a highly selective and fast LC–MS/MS method for accurately measuring levels of tadalafil and finasteride in human plasma, adhering to international bioanalytical guidelines.

This study introduced and validated new spectrophotometric methods to simultaneously determine finasteride and tadalafil in Entadfi™ capsules with high sensitivity and without interference from excipients.

In this study, researchers investigated genetic variants in pharmacogenes affecting tadalafil and finasteride pharmacokinetics, finding fed volunteers had higher drug exposure than fasting individuals, but genetic variation did not significantly impact pharmacokinetics after correcting for multiple comparisons.

In this study, researchers developed a coamorphous form of tadalafil and finasteride, showing improved solubility and dissolution in vitro, with results successfully translated in vivo in rats. They reported reasonable stability, suggesting this form could serve as a therapeutic alternative to the current marketed combination.

In this study, researchers created a coamorphous system combining tadalafil and finasteride that demonstrated improved solubility, dissolution, and stability compared to their physical mixture, offering potential therapeutic advantages for benign prostatic hyperplasia.

In this study, researchers developed a reliable HPLC method to simultaneously estimate Finasteride and Tadalafil in marketed formulations, showing precise, linear results with confirmed degradation susceptibility under certain stress conditions.

This study describes a new LC-MS/MS method for analyzing Finasteride and Tadalafil, demonstrating system suitability, linearity, and accuracy in pharmacokinetic studies in rats, aligning with USFDA guidelines.

This study developed a synchronized fluorescence spectroscopic approach to quantify finasteride and tadalafil in various forms, achieving high accuracy with %recoveries of about 99.62% and 100.19% respectively, and demonstrated superior environmental friendliness compared to previous methods.

This study found that tadalafil use was associated with a decreased risk of major adverse cardiac events and venous thromboembolism in men with lower urinary tract symptoms.

This study found that two eco-friendly analytical methods for quantifying Finasteride and Tadalafil in a new dosage form were effective, green, and suitable for quality control.

Entadfi, a mix of finasteride and tadalafil, is used for BPH.

This review provides a comprehensive overview of the mechanisms, efficacy, and adverse reactions of drugs commonly used for treating benign prostatic hyperplasia but reports no new clinical results.

Combining medications is more effective for treating benign prostatic syndrome symptoms.

Doxazosin and finasteride negatively affect sexual function in men with BPH.

This study found that coadministration of tadalafil and finasteride improved lower urinary tract symptoms and erectile function in men with benign prostatic hyperplasia better than finasteride alone over 26 weeks.

Tailored treatment is crucial for elderly men with BPH due to potential risks and benefits of medications.

This literature review identified that phosphodiesterase 5 inhibitors, such as Tadalafil, are highly effective in improving lower urinary tract symptoms associated with benign prostatic hyperplasia, while the efficacy of saw palmetto remains inconsistent.

This abstract is a website placeholder and reports no research findings or results; it contains navigation and policy information for JAMA Dermatology.

This study found that PRP injections may safely improve penile curvature and PDQ scores in men with stable-phase Peyronie's Disease, although the curvature reduction observed was not enough to determine long-term clinical significance.

This study found that among ten identified medications associated with ejaculatory disorders, Paroxetine and Tamsulosin were mainly linked to delayed and retrograde ejaculation, while Finasteride and Sildenafil were most associated with painful ejaculation and ejaculation failure according to reports from FDA-FAERS and Eudra-Vigilance databases.

This article reviews guidelines and medications for treating benign prostatic hyperplasia but presents no new clinical results.

This study found that phosphodiesterase inhibitors may suppress the proliferation of benign prostatic hyperplasia epithelial cells by modulating CCL5 levels in low androgen conditions.

BPH treatment improved with personalized medicine, new drugs, and less invasive surgeries.

The FDA approved using Cialis with Proscar for better treatment options.

This study introduces three spectrophotometric techniques for accurately determining finasteride and tadalafil in their combined pharmaceutical form, demonstrating their sustainability, sensitivity, and suitability for quality assurance, alongside a dissolution study following FDA guidelines.

In this study, researchers used computational modeling and virtual screening to identify two FDA-approved drugs, Tadalafil and Finasteride, that may effectively inhibit key proteins involved in melanoma progression, suggesting potential for new therapeutic strategies against aggressive melanoma.

This study analyzed the FDA Adverse Event Reporting System and found distinct safety signals and adverse event patterns among α1-blockers, 5α-reductase inhibitors, and tadalafil used in treating benign prostatic hyperplasia, emphasizing known risks and identifying potential new ones that require further study.